Member Info for gixer

Mj33, "BYHEALTH exclusive supply and distribution rights to commercialise Fruitflow in Mainland China, Hong Kong, Macau, Taiwan and Australia (the 'Territories')."

As for product launches, I think the last big (ish) one was Heartisafe in India back in Dec last year. Unfortunately not all products say "Fruitflow" in the ingredients and may call it Tomato extract or concentrate etc in their own language making it difficult picking up on some in the passed.

The company has said that they are " dealing with numerous sales enquiries from existing and new customers for further direct sales of Fruitflow in 2026 and beyond." so we can only wait and see what happens. :(

Some more By-Health investors thoughts.

https://caifuhao.eastmoney.com/news/20260427155651433138950?from=guba&name=5rGk6Iej5YCN5YGl5ZCn&gubaurl=aHR0cHM6Ly9ndWJhLmVhc3Rtb25leS5jb20vbGlzdCwzMDAxNDYuaHRtbA%3D%3D

Yes sphinx, that statement is a bit of a strange one. Do you not think B-H would have known the cost of or negotiated a price for FF before they started? I cant believe that they now think its too expensive after all the work and expense they have gone through.

I have never seen any evidence from B-H to back that posters statement up. I am sure as volume increases cost will come down. BWTFDIK :)

The Q4 Quote or more like a question "will the Qingluosu product be approved in Q4? was all from the same poster @Dongfeng6 东风6号

Seems like he is as in the dark as the rest of us.

By-Health Q1 results have just been released.

Been a lot of recent chat regarding timeline and cost.

What I take from the links below is that nobody in China knows very much :)

No particular order and some might be repeated.

https://xueqiu.com/4664210191/383709958/402738769

https://xueqiu.com/1079817603/383539886/402574759

https://xueqiu.com/1079817603/383539886/402708364

https://xueqiu.com/1079817603/383539886/402711116

https://xueqiu.com/1079817603/383539886/402691024

https://xueqiu.com/2758309497/385180878/403860114

https://xueqiu.com/1079817603/383539886/402737414

https://xueqiu.com/1079817603/383539886/402692284

https://xueqiu.com/1079817603/383539886/402700232

https://xueqiu.com/2758309497/385180878/403872828

https://xueqiu.com/4664210191/383709958/402739198

https://xueqiu.com/4664210191/383754997/402739397

Suppose it would depend how much supplementary material was needed.

Hopefully it wasn't much and it just a box ticking exercise now but who knows.

Snippet. 2026-04-22

Investor: Have the supplementary materials for Xinluosu been submitted?

Tomson Group Board Secretary: Dear Investor, The supplementary materials for the above-mentioned new function application and product registration application have been submitted and are currently under review.

https://stock.stockstar.com/RB2026042200043127.shtml

Https://www.facebook.com/asim.duttaroy.378/posts/pfbid0EtXNiNjYj6WPe1krsvKjEN2awH6R8dJ6jGtHeuRJp9cHYubHMnkYyTAzaae5CAqXl

Born on 8 July 1955 in the village of Gopinagar (also referred to as Gangnapur), in the Nadia district of West Bengal, India

Probably nothing to do with us but you never know with the new product launch in India and the academy, that I forget the name right now, doing work with Asim.

😂😂😂

Thank but I don't think so 👍

Just a coincidence (probably) or something we should know about.

Provexis FourPillars Private Limited.

Incorporated on the 18th of April in India.

https://www.falconebiz.com/company/PROVEXIS-FOURPILLARS-PRIVATE-LIMITED-U56290WR2026PTC293567

PXS bought the remaining stock from DSM and payed for the royalty payment in shares.

The shares were issued to DSM Venturing.

Perhaps DSM just needed to balance the books or pay for a trial????

At least we now know who was selling

I am surprised that they actually notified, and so quickly.

Yes she was responsible for the DO-HEALTH trial. it was a large-scale European study (2,157 participants, aged 70+) investigating whether combining Vitamin D (\(2000\) IU/day), Omega-3 (\(1\text{g}\)/day), and a simple home exercise program (SHEP) could improve health outcomes in older adults.

funded by the European Commission Framework, DSM, Roche, NESTEC, Pfizer, STREULI Pharma etc.

Includes Fruitflow

https://clinicaltrials.gov/study/NCT07523061

Around 40 trades all at 10:30:01

Tootight, It wont make you feel any better but By-Health are keeping their investors pretty much in the dark about progress as well.

And another.

It would seem the Chinese investors in B-H are getting impatient as well.

" Investor Question:

Hello, Qingluosu was expected to launch in early April. What caused the delay? President Li said that PCC1 is about to be launched. When is that?

The company secretary's response ( SZ300146):

Dear investors, the company has submitted applications for new functions and product registration related to Qingluosu, which are currently under review. Please refer to the company's official announcements for the latest product information. Thank you for your attention."

https://finance.sina.cn/stock/relnews/dongmiqa/2026-04-13/detail-inhukeew2316762.d.html?ttid=gwy21c

Now this pops up.

"According to NBD AI News, an investor asked on the investor interaction platform: Is the company's Qingluosu project progressing smoothly? What proactive measures has the company taken during the project approval process? As an industry leader, why is it taking eight years for a product to be launched? Is it because the company is a private enterprise that it is being suppressed? We hope the company will fulfill its promises to investors as soon as possible!

On April 13, By-Health (300146.SZ) stated on its investor interaction platform that the company has submitted applications for new functions and product registration related to Qingluosu, which are currently under review."

https://m.sohu.com/a/1009039275_115362?scm=10001.325_13-325_13.0.0-0-0-0-0.5_1334

So "in the material supplementation stage" a couple of days ago and now back to "currently under review"

No idea whats going on but hopefully the supplemented material is now under review. If that makes sense.